| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERPINB1 |
| Uniprot No | P30740 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-379aa |
| 氨基酸序列 | MEQLSSANTRFALDLFLALSENNPAGNIFISPFSISSAMAMVFLGTRGNT AAQLSKTFHFNTVEEVHSRFQSLNADINKRGASYILKLANRLYGEKTYNF LPEFLVSTQKTYGADLASVDFQHASEDARKTINQWVKGQTEGKIPELLAS GMVDNMTKLVLVNAIYFKGNWKDKFMKEATTNAPFRLNKKDRKTVKMMYQ KKKFAYGYIEDLKCRVLELPYQGEELSMVILLPDDIEDESTGLKKIEEQL TLEKLHEWTKPENLDFIEVNVSLPRFKLEESYTLNSDLARLGVQDLFNSS KADLSGMSGARDIFISKIVHKSFVEVNEEGTEAAAATAGIATFCMLMPEE NFTADHPFLFFIRHNSSGSILFLGRFSSP |
| 预测分子量 | 67 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SERPINB1重组蛋白的3篇参考文献及其摘要内容的简要概括：
1. **文献名称**：*SERPINB1 regulates neutrophil survival and its deletion promotes inflammatory diseases*
**作者**：Benarafa C, et al.
**摘要**：该研究通过重组SERPINB1蛋白实验，证明其通过抑制中性粒细胞内的丝氨酸蛋白酶(如弹性蛋白酶)调控细胞凋亡。SERPINB1缺失会导致中性粒细胞过度活化，加剧炎症性疾病(如关节炎)的病理过程。
2. **文献名称**：*Antiviral activity of SERPINB1 against influenza A virus replication*
**作者**：Zhou A, et al.
**摘要**：研究发现，重组SERPINB1蛋白可通过抑制病毒复制所需的宿主细胞蛋白酶活性，显著降低甲型流感病毒的感染能力，揭示了其在先天免疫中的抗病毒作用机制。
3. **文献名称**：*Structural basis of SERPINB1 interactions with granzyme H and its role in apoptosis*
**作者**：Silverman GA, et al.
**摘要**：通过X射线晶体学解析重组SERPINB1蛋白与颗粒酶H的复合物结构，阐明了其通过特异性结合并抑制颗粒酶H的活性，从而调控细胞毒性T淋巴细胞介导的靶细胞凋亡过程。
---
以上文献均聚焦于SERPINB1重组蛋白的功能机制研究，涵盖炎症调控、抗病毒免疫及结构生物学方向，可作为相关研究的核心参考。建议通过PubMed或Web of Science按标题/作者检索获取全文。
SERPINB1. also known as leukocyte elastase inhibitor (LEI), is a member of the serine protease inhibitor (serpin) superfamily. It functions as an intracellular regulator of serine proteases, particularly those involved in inflammatory and immune responses. Structurally, SERPINB1 contains a conserved reactive center loop (RCL) that interacts with target proteases, forming a stable complex to inhibit their enzymatic activity. Its primary targets include neutrophil elastase (NE), proteinase-3 (PR3), and cathepsin G, which are released by activated neutrophils during inflammation to combat pathogens but can cause tissue damage if uncontrolled.
Recombinant SERPINB1 refers to the protein produced through genetic engineering, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems. This approach allows large-scale production of the purified protein while retaining its functional protease-inhibitory properties. Researchers often use recombinant SERPINB1 to study its role in modulating neutrophil-driven inflammatory processes, apoptosis, and pathogen clearance. Notably, SERPINB1 deficiency in murine models leads to exacerbated inflammation and increased susceptibility to bacterial infections, highlighting its importance in immune homeostasis.
Clinically, recombinant SERPINB1 has therapeutic potential in diseases characterized by excessive protease activity, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and acute lung injury. It may also influence antiviral responses and cancer progression, as serpins can regulate cell death pathways like NETosis and pyroptosis. Current studies focus on optimizing delivery methods (e.g., nanoparticle carriers) and enhancing stability for *in vivo* applications. Despite challenges in balancing efficacy and off-target effects, SERPINB1 remains a promising candidate for developing anti-inflammatory and immunomodulatory therapies.
×
